AstraZeneca (LON: AZN) Shares Plunge Up to 9% After Wainua Misses Primary Endpoint in Late-Stage Trial

AstraZeneca shares plunged as much as 9.55% on Thursday, July 9, 2026, after a major trial setback. The company’s heart drug Wainua failed to meet its primary endpoint in a Phase III study. That single announcement wiped out between £19 billion and £20 billion in market value. AstraZeneca’s market capitalization fell below £200 billion, though it remains the FTSE 100’s second-largest company. Here’s a complete breakdown of what happened, and what it means for AstraZeneca going forward.

What Happened In AstraZeneca’s Wainua Trial

AstraZeneca’s Wainua, developed alongside U.S. partner Ionis Pharmaceuticals, targets a rare heart disease. The CARDIO-TTRansform trial tested Wainua in patients with transthyretin-mediated amyloid cardiomyopathy, called ATTR-CM. Results showed no statistically significant reduction in cardiovascular deaths or recurrent events.

The study tracked patients for up to 140 weeks, comparing Wainua against a placebo. Adding Wainua to standard care, which included a stabiliser drug, offered no measurable clinical benefit. AstraZeneca noted a subgroup using Wainua as monotherapy showed a nominally significant improvement.

Why This Trial Mattered So Much

Citi analysts had modeled peak Wainua sales in ATTR-CM near $6.2 billion, with a 59% success probability. That made CARDIO-TTRansform the bank’s highest-conviction readout among three major AstraZeneca trials due in 2026. The other two, SERENA-4 and AVANZAR, remain pending for later this year.

AstraZeneca and Ionis Pharmaceuticals' Wainua (eplontersen) fails primary endpoint in Phase 3 CARDIO-TTRansform trial for transthyretin-mediated amyloid cardiomyopathy / X https://t.co/gTLkZzWKTa

— HEM News Agency (@halfeatenmind) July 9, 2026

This failure removes one of AstraZeneca’s largest near-term pipeline opportunities from consideration. Citi maintains the setback does not threaten the company’s broader 2030 sales targets, however.

How Much Value AstraZeneca Actually Lost

AstraZeneca shares (NYSE: AZN) fell between 8.6% and 9.55% across various trading snapshots on Thursday morning. That range translated into a market value loss of roughly £19 billion to £20 billion. AstraZeneca’s market capitalization dropped below the £200 billion threshold for the first time recently.

Despite this decline, AstraZeneca still ranks as the second-largest company on the FTSE 100 (^FTSE) index. HSBC leads at approximately £248 billion, while Shell trails AstraZeneca at around £169 billion. This context shows AstraZeneca remains a heavyweight constituent despite Thursday’s sharp single-day drop.

Analyst Reactions To The Setback

Jefferies analyst Michael Leuchten described the trial failure as surprising, given AstraZeneca’s typically strong execution record. He estimated roughly 2% of AstraZeneca’s net present value sat at risk from this result. Leuchten also warned the share reaction could exceed that direct financial calculation.

That warning stems from concerns about management credibility rather than the trial’s isolated financial impact. AstraZeneca’s leadership had expressed strong confidence in Wainua’s primary endpoint before results were released. AlphaValue separately described the failure as a major setback for the company’s cardiovascular pipeline.

AstraZeneca’s Official Response

Sharon Barr, AstraZeneca’s head of biopharmaceuticals research and development, addressed the disappointing result directly. She said the results still support greater scientific understanding of treatment approaches for ATTR-CM patients. AstraZeneca emphasized that Wainua’s safety profile remained consistent with previously observed data throughout the study.

The company maintains its target of reaching $80 billion in annual sales by 2030 remains unaffected. Citi continues rating AstraZeneca shares a Buy, forecasting an 11% rise in earnings per share. AstraZeneca’s next quarterly earnings report is scheduled for July 27, 2026.

What This Means For AstraZeneca’s Pipeline

AstraZeneca still has $46 billion in risk-adjusted peak pipeline sales potential, according to Citi’s broader estimates. Ten Phase III trial readouts remain due across the company’s pipeline during 2026 alone. Wainua’s failure removes one high-conviction catalyst but leaves substantial remaining opportunity intact.

Investors will now focus closely on the SERENA-4 breast cancer trial and AVANZAR lung cancer study. Both readouts arrive later in 2026 and carry significant weight for AstraZeneca’s next growth phase.

Final Thoughts

AstraZeneca’s near-9% share plunge reflects genuine disappointment over Wainua’s failed cardiovascular trial this week. The setback erased up to £20 billion in value, though AstraZeneca remains the FTSE 100’s second-largest company. Analysts largely maintain confidence in AstraZeneca’s broader pipeline, despite flagging credibility concerns around this specific result. Investors tracking AstraZeneca alongside partner Ionis Pharmaceuticals should watch the upcoming SERENA-4 and AVANZAR trial readouts closely.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.